期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors
1
作者 an-jie guo Qing-Yuan Deng +2 位作者 Pan Dong Lian Zhou Lei Shi 《World Journal of Clinical Oncology》 2024年第8期1002-1020,共19页
Immune checkpoint inhibitors(ICIs)constitute a pivotal class of immunotherapeutic drugs in cancer treatment.However,their widespread clinical application has led to a notable surge in immune-related adverse events(irA... Immune checkpoint inhibitors(ICIs)constitute a pivotal class of immunotherapeutic drugs in cancer treatment.However,their widespread clinical application has led to a notable surge in immune-related adverse events(irAEs),significantly affecting the efficacy and survival rates of patients undergoing ICI therapy.While conventional hematological and imaging tests are adept at detecting organ-specific toxicities,distinguishing adverse reactions from those induced by viruses,bacteria,or immune diseases remains a formidable challenge.Consequently,there exists an urgent imperative for reliable biomarkers capable of accurately predicting or diagnosing irAEs.Thus,a thorough review of existing studies on irAEs biomarkers is indispensable.Our review commences by providing a succinct over-view of major irAEs,followed by a comprehensive summary of irAEs biomarkers across various dimensions.Furthermore,we delve into innovative methodologies such as machine learning,single-cell RNA sequencing,multiomics analysis,and gut microbiota profiling to identify novel,robust biomarkers that can facilitate precise irAEs diagnosis or prediction.Lastly,this review furnishes a concise exposition of irAEs mechanisms to augment understanding of irAEs prediction,diagnosis,and treatment strategies. 展开更多
关键词 IMMUNOTHERAPY Immune checkpoint inhibitors Immune-related adverse events Biomarkers CANCERS
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部